Biocon Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Low debt relative to equity (D/E 0.5x)
Concerns
- Low capital efficiency (ROCE 3.6%)
Today's Price Action
The stock closed at ₹350.7 with no change on the day. Trading volume matched the 20‑day average at 42,57,190 shares, indicating a balanced participation level. The flat price movement suggests neutral sentiment.
Valuation Snapshot
Biocon Limited trades at a forward P/E of 72.5, markedly higher than the sector average, which is effectively zero. The return on equity stands at 1.4%, suggesting modest profitability relative to its capital base. A price‑to‑book ratio of zero reflects that the book value per share exceeds the market price, a situation rarely seen in the healthcare space.
Key Levels to Watch
The current price sits near the lower end of the 52‑week range, with the 52‑week low at ₹318 and the high at ₹447. Open‑interest based resistance around ₹380 and support near ₹340 are observable on the nearest term options chain. The intra‑day high of the last session touched ₹355, while the low remained above ₹345, confirming the narrow trading band around the current level.
Chart Pattern
On the daily chart, a bearish Marubozu candle formed ten trading days ago, reflecting a session where the open was equal to the high and the close equal to the low, denoting strong intra‑day selling pressure. The candle appeared on the daily timeframe, which is the primary horizon for most technical assessments.
Data Summary
Key metrics show a market price of ₹350.7, a P/E of 72.5, a P/B of 0, and an ROE of 1.4%. Volume today equaled the 20‑day average of 42,57,190 shares, and the 52‑week range spans ₹318 to ₹447. The stock’s market capitalisation is reported as ₹0 Cr, indicating that the figure is either not disclosed or negligible for public reporting.
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
BIOCON · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 60.64% | 60.64% | 60.64% | 60.64% | 60.64% | 60.64% |
| FII | 6.55% | 5.63% | 5.90% | 5.93% | 5.66% | 5.67% |
| DII | 14.51% | 13.69% | 14.29% | 14.44% | 15.36% | 15.73% |
| Public | 17.96% | 19.74% | 18.90% | 18.74% | 18.11% | 17.77% |
| Others | 0.33% | 0.32% | 0.28% | 0.25% | 0.22% | 0.21% |
Corporate Events
To consider and approve the financial results for the period ended September 30, 2026
To consider and approve the financial results for the period ended Jun 30, 2026
Dividend - Re 0.50 Per Share
To consider Fund Raising
To consider and approve the financial results for the period ended March 31, 2026 and dividend
Dividend - Rs 0.50 Per Share
Dividend - Re 0.50 Per Share
Dividend - Rs 1.50 Per Share
Latest News
All newsBiocon's Pertuzumab gets EMA CHMP approval recommendation
*Biocon's Pertuzumab gets EMA CHMP approval recommendation.* This marks the first biosimilar to secure a positive opinion under the new tailored clinical approach. The approval paves the way for market entry in Europe, boosting revenue potential. **Pertuzumab** targets a multi-billion dollar oncology segment. 📊 *STOCKS:* $BIOCON | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #BioSimilars
Biocon launches Yesafili, a U.S. biosimilar to Eylea® 2 mg
*Biocon launches Yesafili, a U.S. biosimilar to Eylea® 2 mg* — Biocon has announced the U.S. commercial launch of Yesafili, a biosimilar to Regeneron’s Eylea® 2 mg. The launch marks a **major expansion** into the U.S. ophthalmology market, targeting **$4 billion** in annual sales. This move strengthens Biocon’s global footprint and potential revenue streams. 📊 *STOCKS:* $BIOCON | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Biosimilar
Q4 results for Britannia, BSE, Biocon, Dabur out today
*Q4 results for Britannia, BSE, Biocon, Dabur out today.* Investors await key data on revenue, margins, and guidance. Any **beat or miss** on **₹** expectations could drive volatility in F&O contracts. Watch for management commentary on demand trends and capex plans. 📊 *STOCKS:* BRITANNIA | 🏢 *SECTOR:* Earnings | #HIGHIMPACT #Earnings
Biocon secures 10-year Pertuzumab supply deal in Brazil
*Biocon secures 10-year Pertuzumab supply deal in Brazil*. The 10-year contract marks a significant export win for the company in the Latin American market. **Pertuzumab** is a biosimilar drug used in cancer treatment, strengthening Biocon’s global footprint. This deal enhances revenue visibility for over a decade. 📊 *STOCKS:* $BIOCON | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Pharma
Biocon launches new product commercially
*Biocon launches new product commercially.* This marks a strategic advancement in its biologics portfolio. The commercial launch is expected to drive future revenue growth. **No financial figures** were disclosed in the filing. 📊 *STOCKS:* BIOCON | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #ProductLaunch
Biocon announces pivotal clinical data for Yesafili biosimilar
*Biocon announces pivotal clinical data for Yesafili biosimilar*. Biocon has announced the publication of pivotal clinical data supporting the effectiveness of Yesafili, its biosimilar to Eylea® (Aflibercept), in a press release dated July 09, 2026. The data reinforces the drug’s potential in ophthalmic indications and could support future regulatory approvals and market expansion. Positive clinical outcomes may enhance commercial prospects in the growing biosimilars market. 📊 *STOCKS:* BIOCON | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Pharma
Biocon's partner secures insulin tenders in Malaysia
*Biocon's partner Duopharma Biotech secures key insulin tenders in Malaysia.* This reinforces Biocon’s footprint in diabetes care abroad. The win highlights growing international demand for its insulin products. **No financials disclosed**, but strategic impact is positive. 📊 *STOCKS:* BIOCON | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #DiabetesCare
Biocon issues corporate update via NSE filing
*Biocon issues corporate update via NSE filing.* The company has made a routine disclosure through a 'Company Statement' on the NSE. No **financial figures** or **strategic changes** were specified in the headline. Traders should review the full filing for details. 📊 *STOCKS:* $BIOCON | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Corporate
Biocon issues corporate update via NSE filing
*Biocon issues corporate update via NSE filing.* The company has released a statement under 'Corporate Filing' with no specific financial figures or strategic announcements. Details remain sparse and appear to be procedural or administrative in nature. Traders should await further clarity from the company. 📊 *STOCKS:* BIOCON | 🏢 *SECTOR:* Pharma | #LOWIMPACT #corporateupdate
Biocon issues company statement with no financial impact
*Biocon issues company statement with no financial impact.* The update is a routine corporate filing with no disclosure of financial results, leadership changes, or strategic moves. There are no **revenue**, **profit**, or **guidance** figures mentioned. Traders should monitor for further developments. 📊 *STOCKS:* BIOCON | 🏢 *SECTOR:* Pharma | #LOWIMPACT #corporate
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹4.2K Cr 2.9% | ₹4.3K Cr 9.0% | ₹3.9K Cr 10.8% | ₹4.4K Cr 15.6% | ₹3.8K Cr 6.4% | ₹3.6K Cr 4.6% | ₹3.4K Cr 12.4% | ₹3.9K Cr |
| Op. Profit | ₹834 Cr 0.1% | ₹835 Cr 9.0% | ₹766 Cr 28.9% | ₹1.1K Cr 43.4% | ₹752 Cr 9.8% | ₹685 Cr 10.5% | ₹620 Cr 32.1% | ₹913 Cr |
| OPM | 20.0% 5.3% | 19.0% 0.0% | 19.0% 20.8% | 24.0% 20.0% | 20.0% 5.3% | 19.0% 5.6% | 18.0% 21.7% | 23.0% |
| Net Profit | ₹-52 Cr 139.1% | ₹133 Cr 49.4% | ₹89 Cr 80.6% | ₹459 Cr 466.7% | ₹81 Cr 200.0% | ₹27 Cr 96.9% | ₹862 Cr 286.5% | ₹223 Cr |
| EPS (₹) | 1.08 71.4% | 0.63 173.9% | 0.23 92.0% | 2.87 1266.7% | 0.21 261.5% | -0.13 102.4% | 5.49 385.8% | 1.13 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹16.9K Cr 10.9% | ₹15.3K Cr 3.4% | ₹14.8K Cr 32.1% | ₹11.2K Cr 36.5% | ₹8.2K Cr 14.6% | ₹7.1K Cr 13.4% | ₹6.3K Cr 14.3% | ₹5.5K Cr 33.7% | ₹4.1K Cr 6.0% | ₹3.9K Cr |
| Expenses | ₹13.5K Cr 12.1% | ₹12.0K Cr 4.1% | ₹11.5K Cr 31.7% | ₹8.8K Cr 37.1% | ₹6.4K Cr 14.9% | ₹5.6K Cr 18.4% | ₹4.7K Cr 14.0% | ₹4.1K Cr 25.1% | ₹3.3K Cr 13.1% | ₹2.9K Cr |
| Op. Profit | ₹3.5K Cr 6.7% | ₹3.3K Cr 1.2% | ₹3.2K Cr 33.3% | ₹2.4K Cr 34.5% | ₹1.8K Cr 13.4% | ₹1.6K Cr 1.4% | ₹1.6K Cr 15.1% | ₹1.4K Cr 68.2% | ₹829 Cr 15.4% | ₹980 Cr |
| OPM | 21.0% 0.0% | 21.0% 4.5% | 22.0% 0.0% | 22.0% 0.0% | 22.0% 0.0% | 22.0% 12.0% | 25.0% 0.0% | 25.0% 25.0% | 20.0% 20.0% | 25.0% |
| Other Income | ₹-76 Cr 106.2% | ₹1.2K Cr 42.7% | ₹853 Cr 4638.9% | ₹18 Cr 75.0% | ₹72 Cr 72.3% | ₹260 Cr 30.7% | ₹199 Cr 41.5% | ₹340 Cr 49.1% | ₹228 Cr 31.8% | ₹173 Cr |
| Interest | ₹990 Cr 10.4% | ₹897 Cr 7.9% | ₹974 Cr 132.5% | ₹419 Cr 516.2% | ₹68 Cr 17.2% | ₹58 Cr 10.8% | ₹65 Cr 8.5% | ₹71 Cr 14.5% | ₹62 Cr 138.5% | ₹26 Cr |
| Depreciation | ₹2.0K Cr 16.0% | ₹1.7K Cr 7.5% | ₹1.6K Cr 41.0% | ₹1.1K Cr 36.7% | ₹814 Cr 13.8% | ₹715 Cr 29.5% | ₹552 Cr 23.2% | ₹448 Cr 16.4% | ₹385 Cr 39.0% | ₹277 Cr |
| PBT | ₹448 Cr 76.3% | ₹1.9K Cr 23.7% | ₹1.5K Cr 70.0% | ₹897 Cr 8.7% | ₹983 Cr 8.0% | ₹1.1K Cr 9.9% | ₹1.2K Cr 2.4% | ₹1.2K Cr 99.2% | ₹610 Cr 28.2% | ₹850 Cr |
| Tax % | 18.0% 25.0% | 24.0% 60.0% | 15.0% 46.4% | 28.0% 27.3% | 22.0% 4.8% | 21.0% 22.2% | 27.0% 58.8% | 17.0% 34.6% | 26.0% 36.8% | 19.0% |
| Net Profit | ₹369 Cr 74.2% | ₹1.4K Cr 10.1% | ₹1.3K Cr 101.9% | ₹643 Cr 16.7% | ₹772 Cr 8.7% | ₹846 Cr 2.9% | ₹871 Cr 13.2% | ₹1.0K Cr 121.4% | ₹453 Cr 34.2% | ₹688 Cr |
| EPS (₹) | 2.38 71.8% | 8.44 0.9% | 8.52 121.3% | 3.85 28.7% | 5.4 12.5% | 6.17 1.1% | 6.24 17.2% | 7.54 143.2% | 3.1 39.2% | 5.1 |
| Div Payout | 21.0% 250.0% | 6.0% 0.0% | 6.0% 84.6% | 39.0% 333.3% | 9.0% | 0.0% | 0.0% 100.0% | 7.0% 56.3% | 16.0% 60.0% | 10.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Liabilities | ||||||||||
| Equity Capital | ₹668 Cr 11.3% | ₹600 Cr 0.0% | ₹600 Cr 0.0% | ₹600 Cr 0.0% | ₹600 Cr 0.0% | ₹600 Cr 0.0% | ₹600 Cr 100.0% | ₹300 Cr 0.0% | ₹300 Cr 200.0% | ₹100 Cr |
| Reserves | ₹26.1K Cr 24.2% | ₹21.0K Cr 9.7% | ₹19.2K Cr 11.1% | ₹17.3K Cr 120.5% | ₹7.8K Cr 11.5% | ₹7.0K Cr 15.1% | ₹6.1K Cr 5.3% | ₹5.8K Cr 18.8% | ₹4.9K Cr 3.0% | ₹4.7K Cr |
| Borrowings | ₹16.5K Cr 9.9% | ₹18.4K Cr 12.8% | ₹16.3K Cr 9.7% | ₹18.0K Cr 250.1% | ₹5.1K Cr 14.9% | ₹4.5K Cr 65.0% | ₹2.7K Cr 12.1% | ₹2.4K Cr 7.0% | ₹2.3K Cr 1.7% | ₹2.3K Cr |
| Other Liabilities | ₹19.4K Cr 4.8% | ₹18.5K Cr 5.9% | ₹19.7K Cr 24.2% | ₹15.9K Cr 134.5% | ₹6.8K Cr 6.0% | ₹6.4K Cr 27.8% | ₹5.0K Cr 36.0% | ₹3.7K Cr 44.3% | ₹2.5K Cr 12.9% | ₹2.3K Cr |
| Total Liabilities | ₹62.8K Cr 7.2% | ₹58.5K Cr 5.0% | ₹55.8K Cr 7.8% | ₹51.7K Cr 154.4% | ₹20.3K Cr 10.0% | ₹18.5K Cr 28.3% | ₹14.4K Cr 18.2% | ₹12.2K Cr 22.0% | ₹10.0K Cr 6.3% | ₹9.4K Cr |
Assets | ||||||||||
| Fixed Assets | ₹37.3K Cr 16.6% | ₹32.0K Cr 4.3% | ₹30.6K Cr 4.0% | ₹29.5K Cr 348.6% | ₹6.6K Cr 3.2% | ₹6.4K Cr 6.6% | ₹6.0K Cr 33.5% | ₹4.5K Cr 20.8% | ₹3.7K Cr 2.0% | ₹3.6K Cr |
| CWIP | ₹4.7K Cr 45.3% | ₹8.5K Cr 6.4% | ₹8.0K Cr 9.2% | ₹7.3K Cr 78.0% | ₹4.1K Cr 46.8% | ₹2.8K Cr 27.5% | ₹2.2K Cr 15.6% | ₹1.9K Cr 45.7% | ₹1.3K Cr 55.3% | ₹839 Cr |
| Investments | ₹2.3K Cr 107.0% | ₹1.1K Cr 12.7% | ₹1.0K Cr 51.7% | ₹2.1K Cr 30.3% | ₹1.6K Cr 18.6% | ₹2.0K Cr 102.1% | ₹966 Cr 4.5% | ₹1.0K Cr 49.9% | ₹675 Cr 46.1% | ₹1.3K Cr |
| Other Assets | ₹18.5K Cr 9.3% | ₹16.9K Cr 5.1% | ₹16.1K Cr 25.1% | ₹12.9K Cr 59.6% | ₹8.1K Cr 9.5% | ₹7.4K Cr 39.6% | ₹5.3K Cr 9.8% | ₹4.8K Cr 11.6% | ₹4.3K Cr 17.3% | ₹3.7K Cr |
| Total Assets | ₹62.8K Cr 7.2% | ₹58.5K Cr 5.0% | ₹55.8K Cr 7.8% | ₹51.7K Cr 154.4% | ₹20.3K Cr 10.0% | ₹18.5K Cr 28.3% | ₹14.4K Cr 18.2% | ₹12.2K Cr 22.0% | ₹10.0K Cr 6.3% | ₹9.4K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹4.1K Cr 37.5% | ₹3.0K Cr 59.5% | ₹1.9K Cr 57.3% | ₹1.2K Cr 1.5% | ₹1.2K Cr 9.6% | ₹1.3K Cr 11.1% | ₹1.2K Cr 74.5% | ₹662 Cr 3.4% | ₹640 Cr 72.5% | ₹371 Cr |
| Investing CF | ₹-203 Cr 79.7% | ₹-1.0K Cr 93.0% | ₹-14.3K Cr 758.0% | ₹-1.7K Cr 54.5% | ₹-3.7K Cr 142.6% | ₹-1.5K Cr 114.1% | ₹-703 Cr 2.8% | ₹-684 Cr 34.1% | ₹-510 Cr 55.2% | ₹-1.1K Cr |
| Financing CF | ₹-1.9K Cr 20.5% | ₹-2.3K Cr 117.9% | ₹13.0K Cr 5292.1% | ₹242 Cr 90.6% | ₹2.6K Cr 560.8% | ₹388 Cr 260.3% | ₹-242 Cr 0.8% | ₹-240 Cr 34.8% | ₹-178 Cr 116.7% | ₹1.1K Cr |
| Net Cash Flow | ₹2.0K Cr 627.4% | ₹-380 Cr 159.3% | ₹641 Cr 363.8% | ₹-243 Cr 437.5% | ₹72 Cr 56.4% | ₹165 Cr 21.4% | ₹210 Cr 180.5% | ₹-261 Cr 455.3% | ₹-47 Cr 115.7% | ₹300 Cr |
| Free Cash Flow | ₹1.7K Cr 64.2% | ₹1.0K Cr 710.9% | ₹129 Cr 117.3% | ₹-746 Cr 29.3% | ₹-577 Cr 5.7% | ₹-546 Cr 62.0% | ₹-337 Cr 34.3% | ₹-251 Cr 884.4% | ₹32 Cr 113.0% | ₹-246 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 131d 14.9% | 154d 31.6% | 117d 27.2% | 92d 19.5% | 77d 8.5% | 71d 17.4% | 86d 8.5% | 94d 13.3% | 83d 6.4% | 78d |
| Inventory Days | 346d 6.0% | 368d 13.0% | 423d 36.9% | 309d 1.6% | 304d 15.6% | 263d 32.2% | 199d 23.6% | 161d 0.6% | 160d 4.6% | 153d |
| Days Payable | 460d 1.5% | 467d 21.9% | 383d 77.3% | 216d 12.2% | 246d 1.2% | 243d 5.2% | 231d 3.1% | 224d 19.8% | 187d 8.7% | 172d |
| Cash Conv. Cycle | 18d 67.3% | 55d 65.0% | 157d 14.7% | 184d 37.3% | 134d 47.3% | 91d 71.7% | 53d 71.0% | 31d 45.6% | 57d 3.4% | 59d |
| Working Capital Days | -63d 7.4% | -68d 2366.7% | 3d 95.8% | 71d 787.5% | 8d 125.8% | -31d 1450.0% | -2d 133.3% | 6d 75.0% | 24d 300.0% | -12d |
| ROCE | 6.0% 0.0% | 6.0% 0.0% | 6.0% 33.3% | 9.0% 10.0% | 10.0% 23.1% | 13.0% 0.0% | 13.0% 62.5% | 8.0% 33.3% | 12.0% 33.3% | 9.0% |
Source: Screener.in · Lower days = better efficiency
Deep Dive Analysis
About Biocon Limited
Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195)
HealthcarePharmaceuticals & Biotechnology